Abstract
S-phase kinase-associated protein 2 (SKP2) is a well-studied F-box protein and a critical part of the Skp1-Cul1-Fbox (SCF) E3 ligase complex. It controls cell cycle by regulating the expression level of p27 and p21 through ubiquitination and proteasomal degradation. SKP2-mediated loss of p27Kip1 is associated with poor clinical outcome in various types of cancers including hematological malignancies. It is however well established that SKP2 is an oncogene, and its targeting may be an attractive therapeutic strategy for the management of hematological malignancies. In this article, we have highlighted the recent findings from our group and other investigators regarding the role of SKP2 in the pathogenesis of hematological malignancies.
| Original language | English |
|---|---|
| Pages (from-to) | 1051-1063 |
| Number of pages | 13 |
| Journal | Leukemia and Lymphoma |
| Volume | 59 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 4 May 2018 |
Fingerprint
Keywords
- hematological malignancies
- p27Kip1
- Proteasome pathways
- proto-oncogene
- SKP2
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Cite this
Dysregulated expression of SKP2 and its role in hematological malignancies. / Kulinski, Michal; Achkar, Iman W.; Haris, Mohammad; Dermime, Said; Mohammad, Ramzi M.; Uddin, Shahab.
In: Leukemia and Lymphoma, Vol. 59, No. 5, 04.05.2018, p. 1051-1063.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Dysregulated expression of SKP2 and its role in hematological malignancies
AU - Kulinski, Michal
AU - Achkar, Iman W.
AU - Haris, Mohammad
AU - Dermime, Said
AU - Mohammad, Ramzi M.
AU - Uddin, Shahab
PY - 2018/5/4
Y1 - 2018/5/4
N2 - S-phase kinase-associated protein 2 (SKP2) is a well-studied F-box protein and a critical part of the Skp1-Cul1-Fbox (SCF) E3 ligase complex. It controls cell cycle by regulating the expression level of p27 and p21 through ubiquitination and proteasomal degradation. SKP2-mediated loss of p27Kip1 is associated with poor clinical outcome in various types of cancers including hematological malignancies. It is however well established that SKP2 is an oncogene, and its targeting may be an attractive therapeutic strategy for the management of hematological malignancies. In this article, we have highlighted the recent findings from our group and other investigators regarding the role of SKP2 in the pathogenesis of hematological malignancies.
AB - S-phase kinase-associated protein 2 (SKP2) is a well-studied F-box protein and a critical part of the Skp1-Cul1-Fbox (SCF) E3 ligase complex. It controls cell cycle by regulating the expression level of p27 and p21 through ubiquitination and proteasomal degradation. SKP2-mediated loss of p27Kip1 is associated with poor clinical outcome in various types of cancers including hematological malignancies. It is however well established that SKP2 is an oncogene, and its targeting may be an attractive therapeutic strategy for the management of hematological malignancies. In this article, we have highlighted the recent findings from our group and other investigators regarding the role of SKP2 in the pathogenesis of hematological malignancies.
KW - hematological malignancies
KW - p27Kip1
KW - Proteasome pathways
KW - proto-oncogene
KW - SKP2
UR - http://www.scopus.com/inward/record.url?scp=85027375927&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85027375927&partnerID=8YFLogxK
U2 - 10.1080/10428194.2017.1359740
DO - 10.1080/10428194.2017.1359740
M3 - Review article
VL - 59
SP - 1051
EP - 1063
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 5
ER -